Leflunomid Heumann (Leflunomide)

Leflunomide is metabolised to teriflunomide, which blocks the enzyme dihydroorotate dehydrogenase. This inhibition curtails de novo pyrimidine synthesis, limiting the proliferation of activated lymphocytes and thereby reducing the autoimmune inflammation that drives joint disease.

The exact dose of Leflunomid Heumann is set by the prescribing clinician based on the patient’s disease severity, age, liver function, concomitant medicines and overall health status. Dosage adjustments are made according to clinical response and safety monitoring.

Leflunomid Heumann is not recommended for use in pregnancy because leflunomide is known to be teratogenic. Safety during breastfeeding has not been established, so the drug should be avoided unless the benefits clearly outweigh the potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both leflunomide and methotrexate are conventional DMARDs, but leflunomide primarily inhibits pyrimidine synthesis while methotrexate interferes with folate metabolism. Leflunomide may be preferred when patients cannot tolerate methotrexate’s gastrointestinal side effects, though each drug has a distinct safety profile that guides selection.

Leflunomid Heumann should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept tightly closed, protected from moisture and direct sunlight to maintain product stability.

The medication is supplied as oral tablets. Patients should swallow the tablet whole with a glass of water, with or without food, as directed by their healthcare professional. Consistent daily intake helps maintain therapeutic drug levels.

The most serious adverse events include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and teratogenic effects that can cause birth defects. Prompt medical attention is required if signs of liver dysfunction, severe rash or unexplained fever develop.

Patients with known severe hepatic impairment, active serious infections, a history of hypersensitivity to leflunomide or its metabolites, and women who are pregnant or planning pregnancy should avoid Leflunomid Heumann. Clinicians also assess individual risk before initiating therapy.